Quarterly ResultMay 12, 2026, 07:12 AM
Immatics Q1 Net Loss 57.8M; Anzu-cel Phase 3 Analysis Expected 2026
AI Summary
Immatics N.V. reported a net loss of 57.8 million for Q1 2026, an increase from 39.9 million in Q1 2025, primarily due to higher R&D expenses and lower collaboration revenue. Despite the financial loss, the company highlighted significant clinical progress, including the expected interim and final analysis for its lead PRAME cell therapy, anzu-cel, in 2026, and multiple other clinical data readouts across its portfolio. Immatics maintains a strong financial position with $521.5 million in cash and financial assets, projecting a cash runway into 2028.
Key Highlights
- Net loss increased to 57.8 million in Q1 2026 from 39.9 million in Q1 2025.
- Revenue from collaboration agreements decreased to 7.6 million in Q1 2026 from 18.6 million in Q1 2025.
- Research and development expenses rose to 59.2 million in Q1 2026 from 41.9 million in Q1 2025.
- Cash and cash equivalents, plus other financial assets, totaled $521.5 million ( 453.6 million) as of March 31, 2026.
- Cash reach is projected into 2028.
- SUPRAME Phase 3 interim and final analysis for anzu-cel is expected to be triggered in 2026.
- BLA submission for anzu-cel is anticipated in H1 2027, with commercial launch in H2 2027.
- Phase 1 data for second-generation PRAME cell therapy, IMA203CD8, will be presented at the 2026 ASCO meeting.